AGRX vs. HUGE, MTEM, ABVC, ATHE, ADXN, UPC, GRAY, RNAZ, NCNA, and AEZS
Should you be buying Agile Therapeutics stock or one of its competitors? The main competitors of Agile Therapeutics include FSD Pharma (HUGE), Molecular Templates (MTEM), ABVC BioPharma (ABVC), Alterity Therapeutics (ATHE), Addex Therapeutics (ADXN), Universe Pharmaceuticals (UPC), Graybug Vision (GRAY), TransCode Therapeutics (RNAZ), NuCana (NCNA), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical preparations" industry.
FSD Pharma (NASDAQ:HUGE) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.
Agile Therapeutics received 424 more outperform votes than FSD Pharma when rated by MarketBeat users. Likewise, 66.88% of users gave Agile Therapeutics an outperform vote while only 0.00% of users gave FSD Pharma an outperform vote.
Agile Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 1,309.24%. Given FSD Pharma's higher probable upside, analysts clearly believe Agile Therapeutics is more favorable than FSD Pharma.
FSD Pharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Agile Therapeutics has higher revenue and earnings than FSD Pharma. FSD Pharma is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.
FSD Pharma has a net margin of 0.00% compared to FSD Pharma's net margin of -36.24%. FSD Pharma's return on equity of 0.00% beat Agile Therapeutics' return on equity.
In the previous week, FSD Pharma had 1 more articles in the media than Agile Therapeutics. MarketBeat recorded 2 mentions for FSD Pharma and 1 mentions for Agile Therapeutics. Agile Therapeutics' average media sentiment score of 0.96 beat FSD Pharma's score of 0.00 indicating that FSD Pharma is being referred to more favorably in the media.
1.2% of FSD Pharma shares are owned by institutional investors. Comparatively, 10.9% of Agile Therapeutics shares are owned by institutional investors. 8.5% of FSD Pharma shares are owned by insiders. Comparatively, 0.5% of Agile Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Agile Therapeutics beats FSD Pharma on 9 of the 15 factors compared between the two stocks.
Get Agile Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agile Therapeutics Competitors List
Related Companies and Tools
